Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is well-positioned to enter the market of cancer treatment with their innovative and promising CAR-T therapy, which has shown positive initial efficacy and lower toxicity. The company also has potential for growth through their development of therapies for autoimmune diseases and their exploration of new treatments for lupus nephritis and multiple sclerosis, supported by promising results and potential market growth. Their focus on developing therapies for previously underserved patient populations, such as older and frailer patients, also presents an opportunity for Autolus to gain a significant market share in the industry.

Bears say

Autolus Therapeutics is currently facing a negative outlook due to its high cost of goods sold, significant operating losses, and lack of near-term revenue drivers. Additionally, the company's financials are not strong enough to support its high valuation, making it a risky investment.

Autolus Therapeutics (AUTL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Buy based on their latest research and market trends.

According to 4 analysts, Autolus Therapeutics (AUTL) has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.